在癌症免疫力和免疫治疗中EZH2的调节作用
1Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran; Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
增强肠胃同源2 (EZH2) 驱动癌症进展和免疫逃避. 抑制EZH2可能会增强与免疫疗法相结合的抗癌免疫力,提供对瘤有希望的策略.
科学领域:
- 表观遗传学和癌症生物学
- 免疫学 免疫学 免疫学
背景情况:
- 增强性同源2 (EZH2) 是聚合体抑制剂复合体2 (PRC2) 的一个关键组成部分.
- 癌症中的EZH2过度表达促进免疫逃逸,转移和瘤生长.
- EZH2 影响免疫细胞,包括调节性T细胞 (Tregs),自然杀手 (NK) 细胞,CD8+ T细胞,髓质衍生抑制细胞 (MDSCs) 和瘤相关巨细胞 (TAMs).
研究的目的:
- 调查EZH2在癌症进展和免疫逃避中的作用.
- 探索EZH2抑制作为治疗策略的潜力,特别是与免疫治疗结合使用.
主要方法:
- 该研究的重点是EZH2影响基因表达和免疫细胞功能的分子机制.
- 它检查了药理学EZH2抑制对巨细胞两极分化和免疫反应的影响.
- 这项研究分析了EZH2,免疫疗法 (抗CTLA-4,抗PD-1) 和瘤免疫微环境之间的相互作用.
主要成果:
- 过度表达EZH2通过抑制抗原呈现和促进免疫抑制细胞来促进免疫逃逸.
- 药理学EZH2抑制可以矛盾地促进M2巨细胞的两极分化,表明一种抗性机制.
- 抗CTLA-4治疗后增加的EZH2表达和EZH2后增加的PD-L1抑制表明复杂的免疫调节.
结论:
- EZH2在促进癌症生长和免疫抑制方面发挥着关键作用.
- 将EZH2抑制与免疫疗法 (抗PD-1或抗CTLA-4) 结合起来,可以克服耐药性并重新激发抗瘤免疫力.
- 这种组合疗法有望通过减轻T细胞耗尽和增强抗瘤反应来减缓癌症生长.
更多相关视频
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
00:06An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
相关概念视频
Mitogens and the Cell Cycle
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Epigenetic Regulation
X-chromosome...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Master Transcription Regulators
